Tessie
tasipimidine
Table of contents
Overview
Tessie is a veterinary medicine used for short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
It contains the active substance tasipimidine.
Authorisation details
Product details | |
---|---|
Name |
Tessie
|
Agency product number |
EMEA/V/C/005427
|
Active substance |
Tasipimidine sulfate
|
International non-proprietary name (INN) or common name |
tasipimidine
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QN05CM96
|
Publication details | |
---|---|
Marketing-authorisation holder |
Orion Corporation
|
Date of issue of marketing authorisation valid throughout the European Union |
16/08/2021
|
Contact address |
Orionintie 1 |
Product information
Tessie - EMEA/V/C/005427 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Alleviation of situational anxiety and fear in dogs triggered by e.g. travel, noise, owner departure, veterinary visits.